Proteomic Profiling Prognostic of disease aggressiveness and predictive of differential treatment benefit when selecting between single-agent treatment options Serum proteomic test for patients with advanced NSCLC (EGFR wild-type or status unknown) Measures several acute phase reactant proteins Genomic Profiling ddPCR analysis of cell-free DNA (cfDNA) Targeted liquid biopsy mutation test for patients with NSCLC Rapid, actionable information: driver mutations with proven clinical utility